- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Payers and Providers Experiment With Oncology Payment Models
With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.
Insurers and provider groups are trying a variety of approaches on oncology reimbursement that will remove the incentive for oncologists to use expensive but not necessarily effective chemotherapy drugs and instead place the focus back on quality of care.
These approaches range from care management fees paid on top of drug costs to bundled payments and case rates that completely revamp the way oncologists are reimbursed. Representatives of provider groups and insurers described three separate value-based payment programs for oncology at the Pay for Performance Summit in San Francisco sponsored by Global Health Care, LLC, on March 3.
New cancer drugs are often not cost-effective, said Jennifer Malin, MD, PhD, medical director for oncology solutions and innovation at Anthem Inc. For example, there were 13 new cancer treatments approved by the FDA in 2012, and only one of these extended survival by 6 months. Two more extended survival by four to six weeks, she said, but the average cost of treatment per month for all these therapies is $5900.
Link to the complete article on AISHealth:
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
